Patents by Inventor Anna Yulienva Bogdanova

Anna Yulienva Bogdanova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating sickle cell anemia-related conditions with MK-801 or memantine
    Patent number: 8680042
    Abstract: Sickle cell anemia is a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions, and a prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) blocker is used for the treatment of sickle cell anemia and for manufacture of a medicament for the treatment of sickle cell anemia. Moreover, a method for screening for a compound effective in the treatment of sickle cell anemia comprises contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.
    Type: Grant
    Filed: April 18, 2010
    Date of Patent: March 25, 2014
    Assignee: Universität Zürich Prorektorat MNW
    Inventors: Anna Yulienva Bogdanova, Max Gassman, Jeroen Goede
  • Blockers of NMDA Receptor for the Treatment of Sickle Cell Anemia
    Publication number: 20120116060
    Abstract: Sickle cell anemia is a genetic disease characterized by red blood cells that assume an abnormal, rigid, sickle shape. Acute complications of Sickle cell anemia are treated symptomatically with analgesics and transfusions, and a prophylactic treatment of sickle cell crisis is long term application of hydroxyurea. According to the present invention, an N-methyl D-aspartate receptor (NMDAR) blocker is used for the treatment of sickle cell anemia and for manufacture of a medicament for the treatment of sickle cell anemia. Moreover, a method for screening for a compound effective in the treatment of sickle cell anemia comprises contacting a candidate compound with the NMDAR and selecting said candidate compound as effective if it is found to selectively reduce activity of the NMDAR.
    Type: Application
    Filed: April 18, 2010
    Publication date: May 10, 2012
    Applicant: Universitat Zurich
    Inventors: Anna Yulienva Bogdanova, Max Gassmann, Jeroen Goede